Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Anebulo Pharmaceuticals Inc
(NQ:
ANEB
)
1.550
UNCHANGED
Streaming Delayed Price
Updated: 3:39 PM EST, Nov 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,723
Open
1.650
Bid (Size)
1.530 (18)
Ask (Size)
1.690 (1)
Prev. Close
1.550
Today's Range
1.530 - 1.730
52wk Range
1.460 - 3.300
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
November 13, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
September 25, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
-37.27%
-37.27%
1 Month
-15.30%
-15.30%
3 Month
-19.48%
-19.48%
6 Month
-34.32%
-34.32%
1 Year
-26.89%
-26.89%
More News
Read More
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
July 22, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
September 18, 2023
Via
Benzinga
Anebulo Pharmaceuticals: Q3 Earnings Insights
May 11, 2023
Via
Benzinga
Lifecore Biomedical Announces Cooperation Agreement with 22NW
July 01, 2024
From
Lifecore Biomedical, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
June 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 31, 2024
Via
Benzinga
ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024
May 15, 2024
Via
InvestorPlace
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
May 15, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
February 14, 2024
Via
Benzinga
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
February 13, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
December 21, 2023
Via
Benzinga
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
November 14, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 17, 2023
Via
Benzinga
Anebulo Pharmaceuticals Announces New CEO
October 06, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
October 06, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
September 20, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
August 30, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
September 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 22, 2023
Via
Benzinga
Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication
August 21, 2023
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 21, 2023
Via
Benzinga
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
August 21, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.